AVAX ONE TECHNOLOGY LTD. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AVAX ONE TECHNOLOGY LTD. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.34M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $26.6K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $16.3K | Apr 7, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.34M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $26.6K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $16.3K | Apr 7, 2025 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($21.2K) | Apr 7, 2025 |
| FY2024 | Dec 31, 2023 | $2.7K | Apr 7, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.20M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($16.27M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.73M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($12.87M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.64M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($3.22M) | Mar 30, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.67M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($10.10M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($11.15M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($13.66M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($6.93M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($3.35M) | Mar 30, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.8K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $75.3K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $6.6K | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $615.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $474.3K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $123.9K | Mar 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.45M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($5.27M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($6.51M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($12.08M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($5.14M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($1.85M) | Mar 30, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $194.96M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $10.76M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $17.37M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $21.85M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $11.77M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $3.37M | Mar 30, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.99M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.65M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.80M | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | $11.30M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.77M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.96M | Mar 30, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $186.98M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.11M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $8.56M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $10.54M | Apr 7, 2025 |
| FY2023 | Dec 31, 2021 | $8.00M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $1.40M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $2.99M | Mar 30, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.54M | Mar 31, 2026 |
| FY2024 | Dec 31, 2024 | $294.9K | Apr 7, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($93.98M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($60.78M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($44.51M) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | ($32.77M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($19.90M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($12.52M) | Mar 30, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.14M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $489.9K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $3.88M | Apr 7, 2025 |
| FY2022 | Dec 31, 2022 | $2.27M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $7.78M | Mar 14, 2023 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $1.49M | Apr 7, 2025 |
| FY2023 | Dec 31, 2023 | $11.47M | Apr 1, 2024 |
| FY2022 | Dec 31, 2022 | $11.07M | Mar 14, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (205) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1,011) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | (35) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 14, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (199) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (1,011) | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | (35) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 92.94M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 172,255 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 58,415 | Apr 7, 2025 |
| FY2023 | Dec 31, 2022 | 315,916 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 15.18M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 8.44M | Mar 30, 2022 |